---
schema_version: "secwatch.filing_event.v1"
accession: "0001821586-26-000005"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2026-05-11T23:59:59+00:00"
generated_at: "2026-05-14T18:54:20.541971+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MoonLake aligns with FDA on BLA for sonelokimab in HS; Q1 cash $357.9M

## Summary
- FDA pre-BLA meeting positive; alignment on submission plans, adolescent data inclusion, and safety strategy.
- BLA submission planned for end of Sep 2026; Priority Review decision expected within 60 days.
- Proposed label includes ~43% HiSCR75 response and ~29pp delta-to-placebo from MIRA trial, highest in HS.
- Cash $357.9M as of Mar 31, 2026; runway to end of 2027; up to $400M non-dilutive debt facility available.
- R&D expenses $54.5M (stable); G&A $15.5M with $4.8M accelerated stock option cancellation.

## SEC filing metadata
- accession: 0001821586-26-000005
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2026-05-11T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000182158626000005/0001821586-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000182158626000005/mnlk-20260510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001821586-26-000005
- JSON: https://secwatch.observer/filing/0001821586-26-000005.json
- Plain text: https://secwatch.observer/filing/0001821586-26-000005.txt

## Source-grounded claims
- claim_id: 0ddcf7711f3d09d73d05940c5d7535f97993cce5
  claim: MoonLake Immunotherapeutics reported financial results for first quarter of 2026.
  evidence_excerpt: Today, MoonLake also reported its financial results for the first quarter of 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821586/000182158626000005/0001821586-26-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.